dexamethasone + allantoin + metronidazole

Dexamethasone + allantoin + metronidazole (DAM) is a fixed-dose combination solution developed for intraperitoneal administration during or after abdominal surgery. It is designed to prevent postoperative complications such as intra-abdominal adhesions and postoperative ileus (POI). The formulation combines the anti-inflammatory properties of dexamethasone (a synthetic glucocorticoid), the wound-healing and cell-proliferative effects of allantoin, and the antimicrobial activity of metronidazole. The solution acts by inhibiting the formation of fibrin-rich exudates in the abdominal cavity and enhancing the activity of endogenous tissue plasminogen activator (tPA), thereby promoting fibrinolysis and reducing adhesion formation. Clinical evaluation has primarily taken place in China, notably through Phase 3 trials.

Other names

DAM solutionAMD solutiondexamethasone-allantoin-metronidazole solution